You are here

Multivalent Mucosal Vaccine to Include Swine Influenza

Award Information
Agency: Department of Agriculture
Branch: N/A
Contract: N/A
Agency Tracking Number: 2010-00589
Amount: $90,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: 8.3
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2010
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
4108 WILLOW LN
Brookings, SD 57006
United States
DUNS: 828263785
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Mojun Zhao
 Senior Scientist
 (478) 320-0614
 zhaomojun@gmail.com
Business Contact
 David Francis
Title: President
Phone: (605) 692-6912
Email: francis@brookings.net
Research Institution
N/A
Abstract

We have established that E. coli heat labile enterotoxin (LT) is an excellent mucosal adjuvant (immune enhancer) for stimulating immunity in young pigs and does not cause diarrhea or other adverse reactions when administered by intranasal inoculation, even at a relatively high dosage. Co-administration of LT and the K88 fimbriae from porcine enterotoxigenic E. coli (ETEC; pig scours) strains results in the production of both a intestinal and a systemic immune response and provides solid protection against subsequent challenge with an ETEC strain. Our long-term goal is to construct a multi-pathogen vaccine based on intestinal immune stimulation driven by LT as an adjuvant. The overall objective of the current proposal is to determine whether efficacious immunization against Swine Influenza (SI) can be coupled with ETEC immunization. We will produce non-infectious SI virus-like-particles and administer them along with LT and K88 in a vaccine and subsequently test for protection against the same subtype of SI virus and against ETEC. In future studies, immunization protocols will be optimized, and an assessment will be made of influenza virus strain cross protection. The currently proposed project will show whether LT adjuvant administration can serve as platform technology with which a number of vaccine products can be developed and delivered.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government